Anno I | Numero 6 | Ottobre 2016
Comitato scientifico editoriale: Massimo Di Maio, Silvia Novello
Editore: Intermedia – Direttore Responsabile: Mauro Boldrini
Notizie dalla ricerca
The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC
Over the past few years, there have been considerable advances in the treatments available to patients with metastatic or locally advanced non-small cell lung cancer (NSCLC), particularly those who have progressed on or during first-line treatment. Some of the treatment options available to patients are discussed here, with a focus on checkpoint inhibitor immunotherapies (nivolumab and pembrolizumab) and antiangiogenic agents (bevacizumab, ramucirumab and nintedanib). It is hypothesised that …
Continua a leggere
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Limited evidence exists to show that adding a third agent to platinum-doublet chemotherapy improves efficacy in the first-line advanced non-small-cell lung cancer (NSCLC) setting. The anti-PD-1 antibody pembrolizumab has shown efficacy as monotherapy in patients with advanced NSCLC and has a non-overlapping toxicity profile with chemotherapy. We assessed whether the addition of pembrolizumab to platinum-doublet chemotherapy improves efficacy in patients with advanced …
Continua a leggere
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor …
Continua a leggere
Stereotactic Ablative Radiotherapy and immunotherapy combinations: turning the future into systemic therapy?
Radiotherapy (RT) is effective at cytoreducing tumours and until relatively recently the focus in radiobiology has been on the direct effects of RT on the tumour. Increasingly however the effect of RT on the tumour vasculature, tumour stroma and immune system are recognised as important to the overall outcome. RT is known to lead to the induction of immunogenic cell death (ICD) which can generate tumour-specific immunity. However, systemic immunity leading to "abscopal effects" resulting in …
Continua a leggere
Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy
After the massive approval of checkpoint inhibitors in the treatment of numerous malignancies and settings, checkpoint inhibitors-based combination therapies are emerging as a new therapeutic modality. Nivolumab and pembrolizumab (anti-PD1 agents) were recently approved as second-line treatment in NSCLC after progression on platinum-doublets. In parallel, targeting EGFR/ALK in NSCLC using tyrosine kinase inhibitors (TKI) demonstrated remarkable outcomes and was approved as …
Continua a leggere
Appuntamenti AIOM
XVIII Congresso Nazionale AIOM
Roma, 28 – 30 ottobre 2016
Link all'evento
Dialoghi sull'immunoterapia dei tumori dell'AIOM Campania
Benevento, 18 ottobre 2016
Napoli, 20 ottobre 2016
4th International Conference Translational Research In Oncology
Meldola (FC), 8 novembre 2016
Forlì, 9 – 11 novembre 2016
Nuove Frontiere Diagnostico-Terapeutiche nelle Neoplasie Polmonari, Renali e nel Melanoma
Varese, 12 novembre 2016
LUNG COLLECTION 2016. Costruiamo un algoritmo
Milano, 16 novembre 2016
Master Class in Oncologia. Lung Cancer
Firenze, 17 – 18 novembre 2016
First International Congress
Clinical Needs and Translational Research in Oncology
Reggio Emilia, 28 – 29 novembre 2016
Novità nei Tumori Polmonari
Bolzano, 30 novembre 2016
Immunotherapy Bridge 2016
Napoli, 30 novembre 2016
Questi e altri appuntamenti si possono consultare sul sito AIOM

Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001
Per contattare la redazione e commentare le notizie clicca qui: redazione
Per consultare i numeri arretrati della newsletter clicca qui: archivio
Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI

Questo progetto è stato realizzato con il contributo di